Novasep invests €10m to reinforce bioconjugation services
Will build a new fully integrated ADC manufacturing facility at Le Mans in France
Novasep, a supplier of process development and contract manufacturing services and technologies to the life sciences industry, is to build a fully integrated Antibody Drug Conjugate (ADC) manufacturing facility at its Le Mans site in France in a €10m investment.
The company says the new facility will enable it to complement its current ADC offering with full bio-conjugation services to meet increasing market demand.
The facility will be commissioned in the second quarter of 2016 and will provide contract manufacturing in batch sizes from a few mg to 600g to ADC drug developers to support their clinical trial and commercial development phases.
Thierry Van Nieuwenhove, President of Novasep’s Synthesis Business Unit, said: 'Customers are now searching for a simplified supply chain to produce their ADC and other bio-conjugate drug substances. By integrating our R&D, analytical and manufacturing services within a single unit, we can give customers flexibility, assurance of supply and continuity in supply chains.'
He added: 'Combining chemistry and biology is not a given. Novasep is one of the few CMOs able to produce both commercial-scale ADCs payloads and monoclonal antibodies.'
The new facility will be capable of producing ADCs in full compliance with the highest standards in quality, health, environmental and industrial safety.
'This move is part of our 'back to basics' strategy, forging Novasep’s re-focus on growing core businesses,' said Dr Michel Spagnol, Chairman and CEO of Novasep. 'We are proud to see our Le Mans site continuing its growth in one of the pharmaceutical industry’s most exciting development areas.'